In the circles of specialists, Lidochka is called a new generation drug

Endocrinologists, therapists and psychologists discussed at a round table in Komsomolskaya Pravda the treatment of obesity with tyrzepatide - a substance that acts simultaneously on the receptors of two hormones - GIP and GLP-1, in contrast to semaglutide, which affects only GLP-1.

The reason for the discussion was the registration of the Ministry of Health in April 2026 of the Russian generic "Tirliday": the drug was approved for the treatment of type 2 diabetes and obesity. That's what RTVI says.

Professor Alexander Ametov stressed that obesity should not be considered as a problem of excess weight, but as a violation of metabolic health. According to the WHO, by 2030, a decrease in obesity is not projected in more than 185 countries, and 85-90% of patients with type 2 diabetes are diagnosed with obesity. Tyrzepatide reduces appetite, reduces cravings for sweets, slows the emptying of the stomach and prolongs the feeling of satiety; thanks to binding to albumin, it is administered once a week.

In the SURMOUNT-1 study, participants who received a maximum dose of 15 mg lost almost 23% of their body weight on average and maintained their results during treatment. Among 1,032 people with prediabetes, nearly 99 percent of those who received the drug did not develop diabetes in three years, and the risk of developing it compared to placebo decreased by 94 percent.

The TABFAT study showed that over 24 weeks, tirzepatide increased the activity and volume of brown adipose tissue, and some white fat acquired the properties of metabolically active “beige”. This allows us to consider the drug not only as a means of weight loss, but also as a therapy that affects metabolism.

Doctors warn that treatment should be under the control of an endocrinologist: the drug is contraindicated in medullary thyroid cancer, and in diabetes, kidney disease or taking hypoglycemic drugs, dehydration and hypoglycemia are possible. After discontinuation of therapy, weight and metabolic risks may return if the patient does not change diet, physical activity and receive psychological support.

The participants of the round table noted that a stable result is possible when combining the drug with protein nutrition, a gradual increase in activity and work with a psychologist.

"Tirliday" produces "Pharmasynthesis-Nord" in six dosages - from 2.5 to 15 mg. Nikita Punia, Vice President of Pharmasynthesis Group for Commerce, said that the plant was inspected by the Brazilian regulator ANVISA, and the quality of Tirlidea corresponds to the original drug.

Punia compared the cost of Tirlidei with the price of Mounjaro in Austria: there the initial dosage costs from 330 euros, that is, about 11 times more expensive than Tirlidei. According to the company, over five to six weeks after the start of sales, more than 100,000 people bought the drug. Puniya also said that in the forums, patients call "Tirliday" Lida and Lidochka.